Findings from Cambridge Institute for Medical Research Reveals New Findings on Monoclonal Antibodies (The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease)
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Drugs and Therapies is now available. According to news reporting from Cambridge, United Kingdom, by NewsRx journalists, research stated, "Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels."
The news correspondents obtained a quote from the research from Cambridge Institute for Medical Research, "However, after rituximab some patients develop hypogammaglobulinaemia. We performed a single centre retrospective review of 177 patients with multisystem autoimmune disease receiving rituximab between 2002 and 2010. The incidence, severity and complications of hypogammaglobulinaemia were investigated. Median rituximab dose was 6 g (1-20.2) and total follow-up was 8012 patient-months. At first rituximab, the proportion of patients with IgG L. Low immunoglobulin levels were associated with higher glucocorticoid doses during follow up and there was a trend for median IgG levels to fall after >= 6 g rituximab. 45/115 (39%) with IgG >= 6 g/L versus 26/62 (42%) with IgG
According to the news reporters, the research concluded: "Repeat dose rituximab therapy appears safe with judicious monitoring."
For more information on this research see: The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskeletal Disorders, 2014;15():1-9. BMC Musculoskeletal Disorders can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Musculoskeletal Disorders - www.biomedcentral.com/bmcmusculoskeletdisord/)
Our news journalists report that additional information may be obtained by contacting H. Marco, Cambridge Inst Med Res, Cambridge, United Kingdom. Additional authors for this research include R.M. Smith, R.B. Jones, M.J. Guerry, F. Catapano, S. Burns, A.N. Chaudhry, K.G.C. Smith and D.R.W. Jayne (see also Drugs and Therapies).
Keywords for this news article include: Cambridge, United Kingdom, Europe, Adrenal Cortex Hormones, Antineoplastic Monoclonal Antibodies, Antineoplastics, Antirheumatics, Autoimmune Diseases, Autoimmune Disorders, Biotechnology, CD20 Monoclonal Antibodies, Drugs, Drugs and Therapies, Glucocorticoids, Immune System Diseases, Immunoglobulins, Immunology, Immunoproteins, Medical Devices, Rituximab, Serum Globulins, Therapy, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC